Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of dasatinib in relapsed or refractory diffuse large B-cell lymphoma; trial terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-08-31